Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date

P D Zavras; Y Wang; A Gandhi; K Lontos; G M Delgoffe

doi:10.2147/OTT.S177844

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date

Onco Targets Ther. 2019 Jun 11:12:4543-4554. doi: 10.2147/OTT.S177844. eCollection 2019.

Authors

P D Zavras¹, Y Wang^{2

3}, A Gandhi⁴, K Lontos^{2

5}, G M Delgoffe^{2

6}

Affiliations

¹ Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
³ School of Medicine, Tsinghua University, Beijing, People's Republic of China.
⁴ Blood and Marrow Transplant Program, Department of Medicine, Stanford University, Stanford, CA, USA.
⁵ Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
⁶ Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.

Abstract

Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials.

Keywords: CAR T; DLBCL; diffuse large B cell lymphoma; lymphoma; refractory DLBCL; tisagenlecleucel.

Publication types

Review

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States